A clinical stage pharmaceutical company developing BIO 300 for treating solid tumor cancers and inflammatory lung diseases, aiming to enhance radiation treatment effectiveness and mitigate related side effects. BIO 300 is also being investigated for reducing pulmonary injury due to COVID-19.